1. Introduction {#s0005}
===============

Obesity and diabetes are worldwide health burdens. The incidence of obesity has doubled since 1980 with over 1.9 billion adults overweight in 2014, and globally \> 400 million people have type 2 diabetes. Unfortunately, existing anti-obesity and anti-diabetic therapeutic display insufficient efficacy and adverse effects ([@bb0015]). Therefore, there is a global need for novel therapeutic targets that regulate excessive adiposity and glycemic pathophysiology to treat those populations challenged by adverse clinical outcomes. The nuclear hormone receptor (NR) superfamily is comprised of hormone-dependent transcription factors that translate physiological signals into gene regulation to control metabolism in an organ-specific manner. In the context of metabolic disease, dysfunctional NR signaling results in dyslipidemia, diabetes, and obesity. There are 48 NRs in humans, all implicated in disease, although not all with identified natural ligands; these NRs are denoted as orphans. The NR, RORα, has been implicated in the regulation of glucose and fat homeostasis, but has historically belonged to the orphan class of NRs. However, interest in this specific receptor has been stimulated by the rapid emergence of small molecule agonist and inverse agonists ([@bb0350], [@bb0230]).

Several studies suggest that RORα is a constitutively active receptor. The constitutive recruitment of coactivators such as p300, glutamate receptor interacting protein 1 and steroid receptor coactivator 1 (reviewed in [@bb0085]) by RORα in the absence of exogenous ligands supports a state of constitutive activation of RORα by a common endogenous ligand (such as cholesterol metabolites and intermediates) (reviewed in [@bb0085], [@bb0230]). For example, crystallographic and mass spectrometry studies showed that the RORα-LBD is constitutively bound to endogenous ligands including fatty acids, cholesterol metabolites and all trans retinoic acid (reviewed in [@bb0230]). Furthermore, the basal activity of RORs is highlighted by the observation that natural inverse agonists are exploited (for example ursolic acid) in RORγ reporter assays to identify agonists in reporter assays ([@bb0325], [@bb0060]). Recently, it was confirmed that oxygenated sterols (natural LXR ligands and agonists) function as native ligands, but as inverse agonists for both RORα and RORγ (reviewed in [@bb0230], [@bb0165]). Moreover, the crosstalk between the (oxysterol activated NR) LXR and RORα/γ signaling pathways is underscored by our recent study demonstrating decreased expression of the cholesterol 25-hydroxylase mRNA (encodes the enzyme that produces the LXR agonist 25-hydroxycholesterol, 25-HC) and aberrant phagocytosis in the Rorα-deficient staggerer mice (*sg*/*sg*) ([@bb0365]). New studies ([@bb0370]) implicate Rorα in regulating lipid storage in macrophages in a process modulated by 25-HC levels.

The biological significance of RORα in the regulation of important metabolic pathways is underscored by studies on the (global) Rorα-deficient *staggerer* (*sg*/*sg*) mouse model. For example, analysis of the global Rorα knockout model has revealed that Rorα regulates (i) adiposity ([@bb0185], [@bb0190]), (ii) resistance to diet-induced obesity and hepatic steatosis ([@bb0190]), (iii) thermogenesis and browning/beiging of subcutaneous adipose tissue (SAT) ([@bb0200]), (iv) insulin sensitivity and signaling ([@bb0195]), (v) inflammation and phagocytosis ([@bb0365]) and (vi) lipid droplet homeostasis ([@bb0370]).

Specifically, the Rorα-deficient *sg*/*sg* mice display increased AKT signaling in skeletal muscle ([@bb0195]), improved glucose tolerance and insulin sensitivity. The lean phenotype in *sg*/*sg* mice is associated with reduced serum triglyceride and cholesterol levels ([@bb0190], [@bb0200], [@bb0150], [@bb0220]). In addition, decreased adiposity is associated with an increased metabolic rate and cold tolerance in Rorα-deficient *sg*/*sg* mice. This phenotype involves browning/beiging of SAT, increased uncoupling protein 1 (Ucp1) expression (mRNA and protein) and thermogenic gene expression ([@bb0200]), and significantly increased expression of the (cell-fate controlling) histone-lysine *N*-methyltransferase 1 (Ehmt1), which stabilizes the Prdm16 transcriptional complex. However, the significance of RORα in the regulation of adipose physiology remains unclear as it is difficult to dissect the contribution of this widely expressed receptor from the complex interactions that give rise to the lean phenotype. Several in vitro studies have suggested that RORα transcriptional activity acts to suppress adipocyte differentiation. Embryonic fibroblasts from Rorα-deficient *sg*/*sg* mice displayed enhanced differentiation into functional adipocytes ([@bb0080]) and in 3T3-L1 cells RORα constrained differentiation via increased expression during late adipogenesis ([@bb0265]). However, these authors also report a similar differentiation potentiality in pre-adipocytes sourced from homozygous *sg*/*sg* mice as their heterozygous *sg*/+ counterparts. It is evident that an in vivo investigation of RORα function - specifically in adipose tissue (i.e. an organ/tissue specific mouse model) that can account for the developmental, metabolic and compartmental context, is warranted. Therefore, we generated an adipose-specific RORα 'gain of function' transgenic mouse model in order to further understand the adipose-specific function of RORα in (i) lipid deposition, (ii) glucose tolerance and insulin sensitivity, (iii) obesity, and (iv) gene regulation. This is highly significant within the context of obesity as the capacity to expand the number of adipocyte cells to accommodate increased lipid storage requirements is a key determinant of the degree of metabolic dysfunction that accompanies increased adiposity.

Our studies indicate that (heterozygous, Tg-FABP4-RORα4 *tg*/+) mice with adipose-specific RORα4 expression have impaired glucose tolerance, decreased SAT, and hepatomegaly on a high fat diet, a phenotype often associated with obesity ([@bb0005], [@bb0285], [@bb0355]). RNA-seq, targeted qPCR and canonical pathway analysis suggests that adipose-specific RORα4 phenotype is associated with differential regulation of the fibrosis pathway in adipose and hepatic tissue. For example, genes that encode the extracellular matrix (ECM) collagen proteins are down-regulated in the SAT, but increased in *tg*/+ hepatic tissue. This is in accord with the role of collagen production in adipose development and physiology, as well as adipose plasticity to suit metabolic demands and changes ([@bb0235]) and ectopic/aberrant fat deposition ([@bb0020]).

2. Materials and Methods {#s0010}
========================

2.1. Transgene Plasmid Generation {#s0015}
---------------------------------

hRORα4 was amplified by PCR from pSG5-RZR (courtesy of Dr. OA MacDougald, University of Michigan Medical School, USA ([@bb0035])) using a forward primer containing a *Sal*I cut site: AGCGTCGACCATGATGTATTTTGTGATCG and a reverse primer containing a *Not*I cut site: AATGCGGCCGCTTTACCCATCAATTTG. After SalI/*Not*I double digestion, RZR was subcloned into SalI NotI double digested-pCRII-FABP4 promoter vector ([@bb0210]) to generate FABP4-RORα4 construct and verified by sequencing, prior to pronuclear injection.

2.2. Animals and Tissue Collection {#s0020}
----------------------------------

Generation of Tg-FABP4-RORα4 mice was performed by Transgenic Animal Services Queensland. Pronuclear injection was performed in C57BL/6/CBA mixed background mice. Founders were identified by genotyping and FABP4-RORα4 positive transgenic mouse lines were selected for phenotypic analysis after \> 5 generations of backcrossing to C57BL/6 background. 16 and 32 week old WT and FABP4-RORα4 transgenic littermates (Tg-FABP4-RORα4) were obtained from crossing heterozygous *tg*/+ Tg-FABP4-RORα4 transgenic breeders with C57BL/6 mice. Homozygous *tg*/*tg* Tg-FABP4-RORα4 mice were generated by crossing heterozygous Tg-FABP4-RORα4 males and females. All animals were housed in the Queensland Bioscience Precinct Vivarium (UQ) with a 12 h light-dark cycle. The high fat diet used in this study is as described in ([@bb0280]). Animals were weaned at 4 weeks of age and were fed the standard chow diet ad libitum (which contains 4.6% total fat). In contrast, the high fat diet (SF03-002 Fat Modified Rodent Diet; very high fat modification of AIN93G) used in the study contains 36% fat. Both diets were acquired from Specialty Feeds (Glen Forrest, Western Australia). Experimental mice were weighed weekly. For tissue collection, mice were fasted overnight in a new food-free holding cage and subsequently euthanized. Tissues were collected and immediately snap-frozen in liquid nitrogen and then stored at − 80 °C. All aspects of animal experimentation were approved by The University of Queensland Animal Ethics Committee.

2.3. Intraperitoneal Glucose Tolerance Test and Insulin Tolerance Test {#s0025}
----------------------------------------------------------------------

Blood glucose measurements were obtained from the tail vein of 6 h fasted animals (14--16 weeks old or 22 week old mice on high fat diet) following glucose or insulin challenge, using a blood glucose testing system (Accu-chek Performa; Roche Diagnostics, Castle Hill, NSW, Australia) as described ([@bb0310]). Glucose was administered to each mouse at a dose of 2 g/kg and insulin was given at 1.0 U/kg.

2.4. Insulin Enzyme-linked Immunosorbent Assay (ELISA) {#s0030}
------------------------------------------------------

The ALPCO Mouse ultrasensitive Insulin ELISA assay kit was used for the quantitative determination of insulin plasma from 6 h or overnight fasted mice. All procedures were performed according to manufacturer\'s instructions.

2.5. Protein Extraction and Immunoblot Analysis {#s0035}
-----------------------------------------------

Protein extraction from adipose tissue was previously described ([@bb0200]) with modifications. Inguinal white adipose tissues were homogenized in 1 mM EDTA, 10 mM Tris, and 0.25 M sucrose (pH 7.5) with 1xComplete protease inhibitor and 1xPHOS-STOP (Roche Diagnostics, Mannheim, Germany). Infranatant and pellet were separated from the top layer of fat cake after centrifugation. Detergent was then added to a final concentration of 1% Triton X-100, 1% NP-40, and 0.1% SDS for the infranatant (cytosolic proteins) and pellet (nuclear and membrane proteins) separately, incubated for 30 min and sheared eight times with an insulin syringe. The pellet was sheared multiple times using P200 pipette tips and insulin syringe. Protein concentration was measured with BCA reagent (Thermoscientific; Pierce, Rockford, IL). Immunoblot analysis was performed as described previously except that the membranes were blocked in 5% skim milk and probed with anti-RORα (ab60134 1:1000; Abcam), anti-AKT (\#9272, 1:1000; Cell Signaling Technology, Danvers, MA), pAKT (ser473) (\#4058; 1:1000; Cell Signaling Technology), anti-TBP (sc-204; 1:1000, Santa Cruz Biotechnology), or anti-α-tubulin (\#2144, 1:1000; Cell Signaling Technology).

2.6. Histology {#s0040}
--------------

Hematoxylin and eosin (H&E) staining was performed as described ([@bb0200]), on paraffin-embedded tissues fixed in 10% buffered formalin (Sigma-Aldrich). Accustain® Trichrome Stains (Masson) (Sigma-Aldrich) was used for staining collagen fibers in the liver according to manufacturer\'s instructions. To assess macrophage infiltration into adipose, immunohistochemistry was performed on deparaffinized and re-hydrated sections. Enzymatic antigen retrieval was performed using Proteinase K (20 μg/mL) in TE buffer (50 mM Tris, 1 mM EDTA, pH 8.0) for 3 min at room temperature and rinsed with PBS. Macrophages were detected using a specific primary antibody for F4/80 (rat anti-mouse, Abcam, ab6640) at 4 °C overnight. This was followed by 0.3% H~2~O~2~ treatment to reduce endogenous peroxidase activity, and staining with species-matched horseradish peroxidase-conjugated secondary antibody (goat anti-rat antibody, Santa Cruz Biotechnology) at room temperature for 1 h. All blocking steps were performed in 0.5% BSA/PBS in the presence of 10% species-matched anti-sera. Sections were then counterstained using Mayer\'s hematoxylin and mounted using permanent mounting media. Sections were examined using an Olympus BX-51 microscope with a DP-70 digital camera and DP controller imaging software (Olympus Imaging Systems, PA, USA).

2.7. Blood Lipid Profiling and Measurement of Hepatic Triglyceride Concentration {#s0045}
--------------------------------------------------------------------------------

Measurements of total cholesterol, triglyceride, and non-esterified fatty acid in heparinized plasma samples were analyzed by Clinical Pathology Laboratory, School of Veterinary Science, The University of Queensland (Gatton, Queensland, Australia).

2.8. Nuclear Magnetic Resonance (NMR) and Dual-energy X-ray Absorptiometry (DEXA) Scans {#s0050}
---------------------------------------------------------------------------------------

NMR scanning was performed using a Bruker MiniSpec LF50 (Ettlingen, Germany). Total body percentage fat and percentage lean mass values were extracted from the analysis. DEXA scanning was performed on frozen liver tissues harvested from euthanized overnight-fasted mice (32 weeks of age) and measured for lean mass and fat mass using a PIXImus Densitometer (GE Lunar, Madison, WI).

2.9. Genotyping and Tissue Detection of Transgene Expression {#s0055}
------------------------------------------------------------

Genotyping of mice from Tg-FABP4-RORα4 transgenic lines was performed on toe/tail/ear puncture samples using QuickExtract™ DNA Extraction Solution (Epicentre Biotechnologies, Madison, Wisconsin, USA) according to manufacturer\'s protocol. For confirmation of transgene expression, RNA was extracted from tissues and cDNA synthesis was performed as described ([@bb0270], [@bb0255]). SYBR primers were designed using Primer Express (Applied Biosystems, Foster City, CA) for the following: mouse *Rorα* forward CAATGCCACCTACTCCTGTCC and reverse GCCAGGCATTTCTGCAGC for real-time endogenous expression and genotyping, and human *RORα* reverse CTACGGCAAGGCATTTCTGTAAT for real-time ectopic expression and genotyping. The same forward primer was used for both real-time endogenous and ectopic expression.

2.10. RNA Extraction and Purification and cDNA Synthesis {#s0060}
--------------------------------------------------------

Total RNA was extracted using TRI-Reagent (Sigma-Aldrich, St. Louis, MO) and RNA purification was performed using the RNeasy mini kit (Qiagen, Clifton Hill, Victoria, Australia) according to the manufacturers\' instructions. Complementary DNA (cDNA) was synthesized from 0.5--2 μg of purified total RNA using Superscript III Reverse Transcriptase (Invitrogen) and random hexameric primers according to the manufacturer\'s instructions.

2.11. qPCR Analysis {#s0065}
-------------------

Relative expression of genes was determined using the Applied Biosystems (ABI) ViiA™ 7 Real-Time PCR System (ABI, Singapore) as previously described ([@bb0190], [@bb0365]). Relative gene expression was analyzed by qPCR using either TaqMan Gene Expression Assays (ABI, Foster City, CA), or TaqMan low-density arrays (TLDAs) as described ([@bb0280]), or primers designed for use with SYBR master mix. Assay on demand primers for TaqMan qPCR used are described ([@bb0185], [@bb0200]) and include the following: total *RORα* (mouse + human; Mm00443103_m1), *Tle3* (Mm00437097_m1), *Ehmt1* (Mm00553234_m1), *Prdm16* (Mm00712556_m1), *Ucp1* (Mm01244861_m1), Cpt2 (Mm00487202_m1), Pnpla2 (Mm00503040_m1), *Adrb3* (Mm00442669_m1), Ndufb5 (Mm00452592_m1), *Dio2* (Mm00515664_m1), and *Pparα* (Mm00440939_m1). The TaqMan primers for the housekeeping genes are as follows: 18s (catalog number: 4319413E) and *Gusb* (Mm00446953_m1). Primers for SYBR assays include the following: *Cidea*, CAAACCATGACCGAAGTAGCC and AACCAGGCCAGTTGTGATGAC; Acot11, GATCATGGCTTGGATGGAGAA and GGCCTCGGAAATGGAACAT; Errα, CTCTGGCTACCACTACGGTGTG and AGCTGTACTCGATGCTCCCCT; Mcpt1 ATCATGTATCGCCGCAAACT and CCATCTGGTAGGAGCACATGG. Primers for *Col18a1* that detects long, medium short, and all isoforms were as published ([@bb0020]). The SYBR primer sets used as endogenous controls are as follows: *Gusb*, GTGAGCAACGCCAAATATGATG and TCCAAATGCCCATAGTCATGATAC; 18s, GATCCATTGGAGGGCAAGTCT and CCAAGATCCAACTACGAGCTTTTT; *Rplp0*, AGATGCAGCAGATCCGCA and GTTCTTGCCCATCAGCACC.

2.12. RNA-seq Analysis and CIBERSORT {#s0070}
------------------------------------

Library preparation and sequencing were performed by the IMB Sequencing Facility at the University of Queensland. Total RNA sample libraries were generated using the Illumina TruSeq Stranded mRNA LT sample preparation kit (Illumina, Part no. RS-122-2101 and RS-122-2102), according to the standard manufacturer\'s protocol (Part no. 15031047 Rev. E October 2013). The mRNA denaturation and elution was performed with 0.1 μg to 0.2 μg of total RNA (depending on amount of sample available) prior to a heat fragmentation step aimed at producing libraries with an insert size between 120 and 200 bp. cDNA was then synthesized from the enriched and fragmented RNA using SuperScript III Reverse Transcriptase (Invitrogen, Catalog no. 18064014) and random primers. The resulting cDNA was converted into double stranded DNA in the presence of dUTP to prevent subsequent amplification of the second strand and thus maintain the strandedness of the library. Following 3′ adenylation and adaptor ligation, libraries were subjected to 15 cycles of PCR to produce RNA-seq libraries ready for sequencing. Prior to sequencing, RNA-seq libraries were qualified via the Agilent Bioanalyzer with the High Sensitivity DNA kit (Integrated Sciences, Part no. 4067-4626). Quantification of libraries for clustering was performed using the KAPA Library Quantification Kit - Illumina/Universal (KAPA Biosystems, Part no. KK4824) in combination with the Life Technologies Viia 7 real-time PCR instrument. Sequencing was performed using the Illumina NextSeq500 (NextSeq control software v1.2/Real Time Analysis v2.1) platform. The library pool was diluted and denatured according to the standard NextSeq500 protocol and sequencing was carried out to generate single-end 76 bp reads using a 75 cycle NextSeq500 High Output reagent Kit (Catalog \# FC-404-1005). Reads were aligned to GRCm38.p2 (*Mus musculus*) using STAR ([@bb0075]), and read counts for each gene in the Ensembl annotation were generated using htseq-count in the HTSeq python package ([@bb0025]) and the GENCODE annotation ([@bb0115]). Differential gene expression was detected using the DESeq2 ([@bb0215]) packages in R. To quantify the relative expression levels of distinct cell types from complex tissues, we utilized the CIBERSORT ([@bb0260]). Variance stabilized transformed read count was generated using the DESeq2 package ([@bb0215]) and used as input data for CIBERSORT. The LM22 signature was selected as a default parameter and CIBERSORT was run with 100 permutation. Although the tool and the embedded LM22 signature dataset were not designed for interrogating RNA-seq data, the authors note that "*the linearity assumptions made by our method are likely to hold, as previously suggested*". Enrichment scores were transferred into the stack format as published ([@bb0260]).

2.13. Ingenuity Pathway Analysis {#s0075}
--------------------------------

The canonical pathways and functional analyses were generated through the use of IPA (Ingenuity Systems) from the differential expression gene data set acquired from RNA-seq analysis. In the context of the identification of activation or inhibition of pathways, the z-score algorithm matches the direction of gene changes with expected activated/inhibited state in the canonical pathways (orange indicates predicted activation/positive z-score and blue indicates predicted inhibition/negative z-score).

2.14. Database for Annotation, Visualization and Integrated Discovery (DAVID) Analysis {#s0080}
--------------------------------------------------------------------------------------

The entire gene list of significantly regulated genes identified from the RNA-seq analysis was uploaded onto the web documentation of DAVID. Included in the documentation is a modified Fisher exact probability for 'over-represented' or most relevant biological terms associated with the given gene list where *P* \< 0.05 was considered significant ([@bb0130]). Data was extracted after DAVID annotates, organizes and condenses the data into meaningful biological functions that are associated with the gene list provided.

2.15. Statistical Analyses {#s0085}
--------------------------

Statistical analyses for all other analyses not included in the RNA-seq workflow were performed using GraphPad Prism version 5.0 (GraphPad Software, San Diego, USA). In general, significance was calculated using unpaired two-tailed Student\'s *t*-tests or two-way ANOVAs with Bonferroni\'s post-tests where applicable. Correlation analysis was tested in an assumption-free model and the R^2^ value reports the Pearson correlation coefficient. The associated *P*-value tests whether the correlation effect between groups could be due to random sampling. A small P-value allows for the rejection of the null hypothesis that the correlation is due to random sampling.

3. Results {#s0090}
==========

3.1. Transgenic Overexpression of RORα4 in Adipose Tissue {#s0095}
---------------------------------------------------------

Our previous reports investigating the (global) Rorα-deficient *staggerer sg*/*sg* mouse model, and a transgenic muscle-specific line expressing dominant negative RORα indicated that this NR regulates glycemic control and Akt2 signaling. Further studies in the *sg*/*sg* mouse model indicated this NR regulated fat deposition, and responses to dietary challenges. We were interested in further investigating the specific in vivo functional role(s) of RORα signaling in adipose tissue, a major peripheral tissue involved in energy storage. Therefore, we pursued targeted adipose-specific expression of RORα in transgenic mice. We selected the RORα4 isoform for transgenic expression, because qPCR analysis of subcutaneous, visceral and brown adipose tissues from wild-type (WT) C57BL/6 mice clearly demonstrated that of the two isoforms expressed in rodents (RORα1 and α4), RORα4 was the most abundantly expressed isoform in the three adipose tissue depots ([Fig. 1](#f0005){ref-type="fig"}A).

RORα is a constitutively active NR, and we confirmed the (transcriptional) activity of native RORα4 by examining its ability to transactivate a well-characterized RORα dependent reporter gene (mPCP2tkluc) (Supplementary Fig. 1A). We produced transgenic mice that selectively express a transgene encoding a native (human) RORα4 expressing construct driven by fatty acid binding protein 4 (FABP4) promoter (also known as adipocyte protein 2) to achieve adipose-specific expression. To validate the selective expression of the transgene in adipose tissues, RNA from major organ/tissues (skeletal muscle, liver, kidney and spleen), including inguinal, epididymal and interscapular fat tissue representing the subcutaneous, visceral and brown adipose depots, was extracted from male WT and transgenic \[heterozygous (*tg*/+) Tg-FABP4-RORα4\] mice, and ectopic *RORα4* transgene expression was examined via quantitative real-time PCR (qPCR) relative to 18s rRNA ([Fig. 1](#f0005){ref-type="fig"}B). The heterozygous transgenic mice selectively, predominantly, and abundantly expressed the ectopic human transgene ([Fig. 1](#f0005){ref-type="fig"}B), resulting in significantly increased total (i.e. endogenous mouse and ectopic human) RORα expression ([Fig. 1](#f0005){ref-type="fig"}C) in adipose tissues from *tg*/+ mice relative to WT littermate pairs.

As expected, significantly lower transgene expression was observed in the non-adipose tissues (quadriceps muscle, liver, spleen, and kidney) compared to the adipose tissues. For example, ectopic RORα4 expression was \> 50- and \> 500-fold greater in SAT, relative to spleen and liver, respectively. Western blot analysis was performed to validate RORα overexpression using the proteins from the nuclear fractions obtained from inguinal adipose tissues of WT and heterozygote *tg*/+ mice. We showed that total RORα protein is expressed at a higher level (by \~ 8-fold) in heterozygote transgenic mice (*tg*/+) relative to WT siblings in *n* = 2 littermate pairs (Supplementary Fig. 1B and C). Thus using the published FABP4 promoter ([@bb0120]) for driving adipose expression, we have successfully generated an adipose-specific RORα transgenic mouse line (Tg-FABP4-RORα4).

3.2. Adipose-specific RORα4 Transgene Expression Decreases Weight Gain and Subcutaneous Adiposity {#s0100}
-------------------------------------------------------------------------------------------------

We hypothesized that RORα overexpression in adipose would perturb energy storage and homeostasis. Hence, we compared mice on normal chow and high fat diets (HFD), and examined growth, organ weights, fat deposition etc., after an initial phase where normal chow diet (\< 10% of total calories from fat) was fed ad libitum for 16 weeks, and a second phase where the diet was switched to an energy-dense HFD (\~ 40% of energy from fat) for 14--16 weeks ([Fig. 1](#f0005){ref-type="fig"}D). The control cohort remained on chow for the entire duration.

During the growth phase (4--14 weeks of age), comparable weight gain was observed between transgenic (FABP4-RORα4) heterozygous *tg*/+ ([Fig. 1](#f0005){ref-type="fig"}E) and homozygous *tg*/*tg* mice (Supplementary Fig. 2B) compared to WT littermates on a normal chow diet. We detected no dramatic morphological abnormalities and the tissue weights (normalized to total body weight) of the three adipose depots examined were similar (from 16 week old mice) in WT, *tg*/+ ([Fig. 1](#f0005){ref-type="fig"}F and G) or *tg*/*tg* littermates (Supplementary Fig. 2C), and did not display any significant differences. We conclude that the FABP4-RORα4 transgene did not overtly effect the growth or fat deposition in the three adipose depots of *tg*/+ or *tg*/*tg* littermate mice maintained on normal chow diet.

The heterozygous transgenic mice were subsequently placed on high fat diet (HFD) and examined from 17 to 32 weeks of age (relative to chow diet fed mice as controls). After 8 weeks on HFD, both WT and heterozygous *tg*/+ mice displayed significant increases in weight gain (by \~ 50%) when compared to their respective chow-fed controls (chow-fed for the same duration) ([Fig. 2](#f0010){ref-type="fig"}A and B). However, between HFD-fed WT and *tg*/+ littermate pairs, we observed a marked and statistically significant divergence in weight gain from week 28 (approximately 10 weeks into the diet) and by week 30, *tg*/+ mice averaged 4 g less in weight than WT littermates ([Fig. 2](#f0010){ref-type="fig"}C). In corresponding sets of mice on a normal chow diet, for the same duration, the *tg*/+ mice trended toward less weight gain compared to WT littermates ([Fig. 2](#f0010){ref-type="fig"}D), however, this observation did not attain significance. Thus transgenic mice appear to be leaner on a HFD. Gross anatomical examination of frontal views of mice after dissection revealed a striking decrease in subcutaneous fat deposition in the HFD-fed *tg*/+ mice relative to WT littermates ([Fig. 2](#f0010){ref-type="fig"}E). The difference in adiposity for the HFD-fed *tg*/+ mice is corroborated by an independent measurement of total body fat and lean mass percentage using nuclear magnetic resonance (NMR) scanning. This NMR analysis was performed prior to dissection on non-fasted, live, HFD-fed mice, and showed a significant \~ 25% decrease in percentage total body fat of *tg*/+ mice relative to WT littermate pairs (with a corresponding increase in percentage total lean mass) ([Fig. 2](#f0010){ref-type="fig"}F and G). Adipose depot weight analysis confirmed a significant \~ 40% decrease in the tissue weight of the SAT from HFD fed *tg*/+ mice relative to the corresponding tissue from WT littermate pairs ([Fig. 2](#f0010){ref-type="fig"}H). However, there were no such respective differences in weights of other adipose tissues examined \[visceral (epididymal) adipose tissue and brown (interscapular) adipose tissue\] ([Fig. 2](#f0010){ref-type="fig"}H). This significantly decreased subcutaneous depot mass in the *tg*/+ relative to WT littermates on the HFD was further confirmed by examining the correlation between the visceral (epididymal) vs. subcutaneous (inguinal) fat mass from WT and heterozygous *tg*/+ littermates on chow ([Fig. 2](#f0010){ref-type="fig"}I) and HFD ([Fig. 2](#f0010){ref-type="fig"}J), respectively. We fitted the data points using correlation analysis and it demonstrated the attenuated capacity of the *tg*/+ subcutaneous adipose depot to expand in the face of a HFD challenge, in contrast to the WT littermate ([Fig. 2](#f0010){ref-type="fig"}J). If the overall slopes were identical during the HFD challenge, there is a \~ 1.4% chance of randomly choosing data points that will fit identical slopes, concluding that the differences between the slopes are significant. In contrast, mice fed a chow diet in parallel did not present with any observable (and/or significant differences; \~ 86% chance of randomly choosing data points that will fit the current slope) in fat deposition in WT and *tg*/+ littermates on the chow diet ([Fig. 2](#f0010){ref-type="fig"}I and Supplementary Fig. 1C and D). This type of correlation analysis has been employed previously to characterize depot specific adipose expansion ([@bb0140]).

In summary, our initial observations suggested that adipose-specific RORα4 overexpression prevented overall weight gain by limiting prevents subcutaneous fat expansion and deposition on a high fat diet. The potentially selective effect of the FABP4-RORα4 transgene on SAT fat deposition and expansion, i.e. a selective SAT lipodystrophy, is of particular interest in the light of pre-clinical studies indicating removal of SAT induces glucose intolerance ([@bb0090]), and that intra-abdominal subcutaneous fat transplantation reverses glucose intolerance induced by an energy-dense diet ([@bb0125]).

3.3. Adipocytes From *tg*/+ Subcutaneous Fat Tissue Are significantly Decreased in Median Size {#s0105}
----------------------------------------------------------------------------------------------

We further characterized HFD-induced fat deposition in different types of adipose tissues at a cellular level, by measuring the cross-sectional area of adipocytes in hematoxylin and eosin (H&E)-stained sections of SAT from WT and heterozygous *tg*/+ mice. Staining revealed that adipocytes from the SAT fat pad in *tg*/+ mice were smaller relative to respective cells in WT littermate tissues ([Fig. 3](#f0015){ref-type="fig"}A). This difference was confirmed by quantification, with *tg*/+ mice displaying a higher proportion of adipocytes with smaller cell area and a significant decrease (\~ 50%) in median area relative to WT littermates ([Fig. 3](#f0015){ref-type="fig"}B). This phenotype was not observed in visceral adipose tissue, rather epididymal adipocytes from WT and *tg*/+ mice had a similar cross-sectional area ([Fig. 3](#f0015){ref-type="fig"}C and D). The predictable hyperplasia in response to high fat diet feeding observed in adipocytes from the visceral compartment indicated that *tg*/+ mice did not have a generalized lipid storage defect, rather that excess lipids were being directed away from SAT depots.

3.4. Transgenic Adipose Specific RORα4 Expression Leads to Hepatomegaly and Splenomegaly {#s0110}
----------------------------------------------------------------------------------------

The selective decrease in inguinal (i.e. subcutaneous) adiposity after HFD in Tg-FABP4-RORα4 transgenic mice was somewhat unexpected as previous studies from our group and others reported decreased total adiposity in the homozygous (global) Rorα-deficient *sg*/*sg* mouse line on both normal chow and HFD ([@bb0190], [@bb0200], [@bb0150]). However, in the chow-fed study comparing non-adipose tissues between WT and *tg*/+ mice, we noted that 32 week old *tg*/+ mice displayed a modest decrease in relative quadriceps muscle mass (\~ 15%) and a pronounced enlargement of the liver and spleen (both \~ 30% increased relative weight, [Fig. 3](#f0015){ref-type="fig"}E and G). Dual-energy X-ray absorptiometry (DEXA) scanning of livers from this cohort of chow-fed mice, confirmed significantly increased fat composition (by \~ 30%) in *tg*/+ livers compared to those of WT littermates (in contrast to no changes in the liver lean mass composition) ([Fig. 3](#f0015){ref-type="fig"}F).

An even more striking hepatomegaly and splenomegaly was observed in HFD fed *tg*/+ mice ([Fig. 3](#f0015){ref-type="fig"}H--J). Quantification confirmed the significant weight increase of the liver and spleen in *tg*/+ mice on HFD relative to WT littermates (*n* = 9--10) ([Fig. 3](#f0015){ref-type="fig"}J). Notably, quadriceps muscles were not significantly different in weight between WT and *tg*/+ mice on a HFD ([Fig. 3](#f0015){ref-type="fig"}J).

Collectively, results from the extended chow study point to an age-dependent effect of transgenic FABP4-RORα4 overexpression on hepatic and splenic lipid loading. Due to the lipodystrophy observed in the SAT and the hepatomegaly after HFD, we focused our subsequent attention on the contribution of these tissues to the overall phenotype of the transgenic model.

It has been shown that SAT modulates liver triglyceride accumulation ([@bb0125]). Moreover, failure to sustain or expand adequate subcutaneous fat storage adversely impacts glucose tolerance and contributes to ectopic fat accumulation in non-adipose organs such as the liver, increasing susceptibility to inflammatory stress and cancer ([@bb0090], [@bb0125], [@bb0385]). To gain a histological perspective of the changes in fat deposition of *tg*/+ livers, we performed H&E staining on deparaffinized liver sections from HFD-fed WT and *tg*/+ mice to identify significant morphological differences. We observed a striking increase in vacuole-like lipid bodies in *tg*/+ liver relative to WT littermates (Supplementary Fig. 3A), suggesting increased lipid storage in the *tg*/+ livers could be involved in hepatomegaly ([Fig. 3](#f0015){ref-type="fig"}E and H).

In the liver, steatosis can be accompanied by fibrosis. To check for development of fibrosis in the *tg*/+ livers, we performed Masson\'s trichrome staining to visualize collagen accumulation, a hallmark of fibrosis. In both WT and *tg*/+ livers of mice (fed on a HFD for 14 weeks) we observed signs of portal vein collagen accumulation with no signs of central fibrosis occurring in both strains of mice ([Fig. 4](#f0020){ref-type="fig"}A). A modest increase in collagen-positive portal veins/sites in transgenic liver was present, consistent with early, mild portal fibrosis ([Fig. 4](#f0020){ref-type="fig"}A).

In summary, we observed the development of hepatomegaly and splenomegaly with FABP4-RORα4 transgene overexpression on chow diet. Upon HFD challenge, transgenic mice displayed decreased total body weight associated with a specific decrease in subcutaneous adiposity, and hepatomegaly was further exacerbated. DEXA and histological analyses of transgenic livers showed increased lipid accumulation. This was accompanied by significantly increased levels of circulating triglycerides and NEFA\'s in the Tg/+ mice (relative to WT littermates) on the chow diet ([Fig. 4](#f0020){ref-type="fig"}B and C); however, the blood lipid profiles on the HFD were not significantly different (data not shown). Interestingly, transgenic livers appear to be susceptible to develop mild portal fibrosis, warranting more rigorous characterization of this phenotype. Thus the effect of HFD challenge was to alter the energy storage response in the *tg*/+ mice from the traditional lipid depots (adipose tissues) to non-conventional sites such as the liver, imposing additional stress on these organs. This indicates a poor prognosis for the *tg*/+ mice because disorders in adipose fat storage function can lead to increased liver steatosis, glucose intolerance and cancer ([@bb0385]). Consequently, we investigated the association between aberrant energy storage and glycemic control in the FABP4-RORα4 transgenic mouse model.

3.5. Glucose Intolerance in Tg-FABP4-RORα4 Mice {#s0115}
-----------------------------------------------

Previous studies on the global Rorα-deficient *staggerer* (*sg*/*sg*) mutant mice revealed overall improved glucose tolerance and increased insulin sensitivity ([@bb0195]). Hence we examined the effect of adipose-specific RORα transgene expression on these parameters.

Compared to their WT counterparts, both *tg*/+ (heterozygous) ([Fig. 4](#f0020){ref-type="fig"}D) and *tg*/*tg* (homozygous) (Supplementary Fig. 2D) Tg-FABP4-RORα4 transgenic mice fed on normal chow diets exhibited elevated blood glucose levels after a 6 h fast. We further examined systemic glucose metabolism and insulin sensitivity by performing intraperitoneal glucose tolerance tests (GTTs) and insulin tolerance tests (ITTs). Although blood glucose levels in *tg*/+ mice peaked at a similar level to WT littermate mice, glucose clearance was impaired at the later timepoint -- remaining \~ 40% higher than WT littermates at the end of the time course ([Fig. 4](#f0020){ref-type="fig"}E). Interestingly, glucose clearance in the homozygous *tg*/*tg* mice (that we could only obtain in limited number) was markedly impaired with a significant increase in peak blood glucose levels (\~ 30%) after glucose challenge and sustained higher blood glucose levels were recorded throughout the time course (Supplementary Fig. 2E). The blood glucose level in *tg*/*tg* mice was \~ 65% higher than WT littermates at the end of the time course (Supplementary Fig. 2E). In contrast, WT, *tg*/+ ([Fig. 4](#f0020){ref-type="fig"}F) and *tg*/*tg* (Supplementary Fig. 2F) mice showed similar responsiveness to intraperitoneal insulin, indicating normal insulin action in the transgenic mice. Furthermore, plasma insulin levels in 6 h and overnight fasted *tg*/+ mice were not significantly different than the comparable levels in WT mice \[[Fig. 4](#f0020){ref-type="fig"}J(i and ii)\]. Preliminary intraperitoneal pyruvate tolerance testing also revealed no significant differences between WT and *tg*/+ littermates (data not shown), allowing us to exclude alterations in hepatic gluconeogenesis as a contributor to the impaired glucose clearance observed during IP glucose challenge.

In the HFD study, *tg*/+ mice also displayed significantly higher fasting blood glucose levels (\~ 20% higher) relative to WT littermates ([Fig. 4](#f0020){ref-type="fig"}G). After intraperitoneal administration of glucose, both WT and *tg*/+ mice showed similar peak blood glucose levels (\~ 30% increase compared to those on chow diet) and the impairment in glucose clearance ([Fig. 4](#f0020){ref-type="fig"}H). However, this was more pronounced compared to data from the chow study in [Fig. 4](#f0020){ref-type="fig"}E (blood glucose level in HFD *tg*/+ mice was \~ 50% higher than WT littermates at the end of the time course). While *tg*/+ mice did appear to be less sensitive to insulin administration, this trend did not attain significance ([Fig. 4](#f0020){ref-type="fig"}I). Fasted plasma insulin levels were also not significantly different between WT and *tg*/+ mice ([Fig. 4](#f0020){ref-type="fig"}K. Therefore, the impairment to glucose tolerance in Tg-FABP4-RORα4 mice appears to be independent of insulin action.

In summary, these results demonstrated a dose-dependent negative effect of adipose-RORα expression on whole body glucose clearance -- an effect that was amplified in the context of high fat diet. It is intriguing to speculate whether the SAT lipodystrophy that is observed in this model contributes to compromised glucose tolerance as other studies have indicated it is essential for the maintenance of glycemic control under both normal and high fat dietary conditions ([@bb0090], [@bb0125]).

3.6. Insights Into the Molecular Pathways Underlying the SAT Lipodystrophy and the Hepatomegaly Phenotype in the Tg-FABP4-RORα4 Mice {#s0120}
------------------------------------------------------------------------------------------------------------------------------------

In an effort to gain molecular insights into the SAT lipodystrophy and hepatomegaly, accompanied by glucose intolerance (in the absence of changes in whole body insulin sensitivity, we undertook broad-scale (qPCR and RNA-seq) transcriptional profiling of SAT and the liver in order to identify changes in underlying molecular pathways.

### 3.6.1. Subcutaneous Adipose Gene Expression in Tg-FABP4-RORα4 Mice {#s0125}

Our strategy to identify the gene expression patterns underlying the selective SAT lipodystrophy involved a bifurcated approach, that investigated: (i) specific differences in subcutaneous relative to visceral adipose in the transgenic mouse, and (ii) differences in SAT in the transgenic relative to WT mice.

Initially, we examined the differential expression of genes in subcutaneous relative to visceral adipose (by qPCR) in the transgenic model that may influence lipid homeostasis and glycemic control. This analysis identified significantly decreased expression of several critical genes that drive fatty acid biosynthesis, and lipid droplet expansion including Acs14, Dgat2, Fasn and Scd2 in SAT relative to visceral adipose tissue from the Tg-FABP4-RORα4 ([Fig. 5](#f0025){ref-type="fig"}A--D). Moreover, we observed significantly decreased expression of the Rab-GTPase-activating proteins (Rab-GAPs), Tbc1d1 and AS160/Tbc1d4 ([Fig. 5](#f0025){ref-type="fig"}E and F) in the Tg-FABP4-RORα4 SAT. Decreased expression of Rab GTPase-activating proteins has been reported to correlate with decreased glucose tolerance in an intraperitoneal GTT assay, aberrant glucose uptake and dysfunctional carbohydrate and energy homeostasis ([@bb0110], [@bb0055]). Furthermore, we observed decreased Rab18 expression (that failed to attain significance, *P* = 0.06), which has been associated with impaired fat storage ([@bb0290]), and aberrant processing of lipids in adipose tissue ([@bb0295]) ([Fig. 5](#f0025){ref-type="fig"}F). In summary, this analysis identified the differential expression of several critical genes in SAT (relative to visceral adipose) that provided some insights into the subcutaneous lipodystrophic and glucose intolerant phenotype in the Tg-FABP4-RORα4.

To gain further insights we examined the differential expression of several metabolic genes that may contribute to decreased SAT deposition/expansion (on HFD) in the Tg-FABP4-RORα4 mouse model, relative to WT littermates. We uncovered several gene changes that are consistent with elevated lipid mobilization and catabolism in the SAT. For example, we identified significant up-regulation of the gene encoding carnitine palmitoyltransferase 2 (Cpt2) in the adipose tissue of heterozygote *tg*/+ mice ([Fig. 6](#f0030){ref-type="fig"}A). Cpt2 catalyzes rate-limiting steps in fatty acid uptake and oxidation by mitochondria ([@bb0040], [@bb0145]). In addition, we also observed significant up-regulation of patatin-like phospholipase domain containing 2 \[Pnpla2, also known as adipose triglyceride lipase (ATGL)\] in *tg*/+ SAT ([Fig. 6](#f0030){ref-type="fig"}B). PNPLA2/ATGL is the rate-limiting enzyme that catalyzes the hydrolysis of triglycerides and plays a key role in lipid droplet degradation ([@bb0345]). Moreover, we observed increased expression of the mRNAs encoding the β3-adrenergic receptor (*Adrb3*) ([Fig. 6](#f0030){ref-type="fig"}C) in concordance with increased lipolysis and fatty acid utilization ([@bb0095], [@bb0100], [@bb0250]). Furthermore, the gene that encodes one of the critical NADH dehydrogenases that are part of the mitochondrial complex I machinery (*Ndufb5*) was significantly up-regulated in the SAT of Tg-FABP4-RORα4 *tg*/+ mice ([Fig. 6](#f0030){ref-type="fig"}D). Differential and increased expression of Cpt2, Pnplas/ATGL, Adrb3, and Ndufb5 is entirely concordant with increased lipid mobilization and utilization in the SAT from Tg-FABP4-RORα4 *tg*/+ mice, and would contribute to decreased fat deposition/expansion in this depot by mice that overexpress RORα4 in adipose tissue.

We subsequently investigated gene expression associated with adaptive thermogenesis in the brown adipose tissue from the Tg-FABP4-RORα4 transgenic mouse model, relative to WT littermates. Previously, we identified that decreased adiposity in the Rorα-deficient *sg*/*sg* mice was associated with differential expression of the hierarchical adipose transcriptional regulators (*Ehmt1*, *Tle3*, *Prdm16*), increased Ucp1 expression, and elevated expression of genes associated with the induction of the thermogenic program ([@bb0200]). Therefore, we performed qPCR analysis on selected key thermogenic regulatory genes from chow-fed Tg-FABP4-RORα4 *tg*/+ mice, including *Ehmt1*, *Tle3*, *Prdm16*, *Ucp1* and the accompanying genes associated with thermogenesis (e.g. *Cidea*, *Acot11*, *Dio2*, *Errα*, *Pparα*, and *Mcpt1*). We observed no significant differences in the mRNA expression of the transcriptional regulators, *Ehmt1*, *Tle3* and *Prdm16* in brown adipose tissue (Supplementary Fig. 4), but we observed a significant decrease in the expression of the mRNAs encoding *Ucp1* (by \~ 60--70%) and *Cidea* (by \~ 30--40%) in the brown adipose from Tg-FABP4-RORα4 *tg*/+ mice, relative to WT littermates on the chow and high fat diets, respectively ([Fig. 6](#f0030){ref-type="fig"}E and F vs. [Fig. 6](#f0030){ref-type="fig"}G and H, respectively). However, we did not observe any significant differences in the expression of the other genes involved in the thermogenic program in the brown adipose from Tg-FABP4-RORα4 *tg*/+ mice, relative to WT littermates on the chow and high fat diets, respectively (Supplementary Fig. 4). The decreased expression of Ucp1, is consistent with increased Ucp1 mRNA expression in the Rorα-deficient *sg*/*sg* mouse model, and provides further evidence for the association between RORα signaling and *Ucp1* mRNA expression. Moreover, decreased Cidea expression correlates with increased lipolysis, and decreased triglyceride deposition/lipid droplet formation ([@bb0300]). Overall, the lipodystrophic SAT phenotype in the Tg-FABP4-RORα4 *tg*/+ mice is in accord with gene expression changes that affect lipid homeostasis.

### 3.6.2. RNA-seq and Pathway Analysis {#s0130}

We subsequently performed genome wide RNA-seq expression profiling analysis on RNA collected from SAT and hepatic tissue to gain deeper insights into the underlying molecular pathways. The analysis identified \> 2400 genes/mRNA (total, after Benjamini and Hochberg correction) that were differentially expressed in the SAT in a significant manner. We could also identify that RORα was significantly up-regulated by \~ 10-fold (*P* \< 6.08 × 10^− 89^) in *tg*/+ SAT (Supplementary Table 1, highlighted in gray). In contrast, only \~ 70 genes (total, after Benjamini and Hochberg correction) in the liver were differentially expressed in a significant manner (*n* = 3 littermate pairs). The top 50 up- and down-regulated genes in SAT are listed in Supplementary Table 1 and the up- and down-regulated genes in the liver are listed in Supplementary Table 1.

Ingenuity pathway analysis was performed to identify canonical pathways and biological functions that were significantly enriched with differentially expressed genes from the RNA-seq analysis. This was performed with a cut-off value of ≥±1.3 fold-change (\~ 1800 genes after cut-off). Pathway analysis on SAT identified significant enrichment of differentially expressed genes involved in \~ 140 canonical pathways in Tg-FABP4-RORα4 *tg*/+ mice. The analysis revealed that the differentially expressed genes enrich approximately \~ 20% of each pathway ([Fig. 7](#f0035){ref-type="fig"}A). The top 15 significantly enriched canonical pathways and biological functions are shown in [Fig. 7](#f0035){ref-type="fig"}A. These include (the most highly ranked pathway) hepatic fibrosis (*P* \< 8.28 × 10^− 8^). Interestingly, the pathway analysis also identified significant enrichment of functions associated with endocrine disorders and metabolic diseases, corresponding to glucose metabolism disorder (*P* \< 5.62 × 10^− 24^), insulin-dependent diabetes mellitus (*P* \< 2.39 × 10^− 21^) and diabetes mellitus (*P* \< 1.44 × 10^− 19^) and further predicts that diabetes mellitus is increased (z-score = 2.303) ([Fig. 7](#f0035){ref-type="fig"}B). Interestingly, 10 out of the top 15 significantly enriched canonical pathways are associated with immune signaling and inflammatory response. In summary, this is in accord with the phenotypes of impaired glucose clearance observed and highlights increased susceptibility in developing diabetes mellitus at the transcript level with adipose-specific RORα expression.

Ingenuity pathway analysis of the liver is limited, identifying only 11 canonical pathways as significantly enriched with the list of differentially expressed genes from RNA-seq analysis (\~ 70 genes) between WT and Tg-FABP4-RORα4 *tg*/+ hepatic tissue ([Fig. 7](#f0035){ref-type="fig"}C). Notably, hepatic fibrosis was the most significant pathway in *tg*/+ liver (that displayed hepatomegaly) as discussed previously. The pathway analysis and heatmap depicted in [Fig. 7](#f0035){ref-type="fig"}D, also predicts that pathways associated with PPAR signaling (*P* \< 8.47 × 10^− 3^) and PPARα activation (*P* \< 4.69 × 10^− 2^) are inhibited while IL-6 signaling pathway (*P* \< 1.52 × 10^− 2^) is activated ([Fig. 7](#f0035){ref-type="fig"}C/D). PPARs are well-known NRs that play a central role in fatty acid metabolism (in particular lipid catabolism). IL-6 is a pro-inflammatory cytokine and has been linked to development of hepatic steatosis and hepatic insulin resistance ([@bb0320]). These observations in the hepatic tissue are in accord with increased lipid storage or possible tissue damage/fibrosis in Tg-FABP4-RORα4 *tg*/+ livers. Moreover, functional DAVID pathway analysis of the liver (Supplementary Fig. 3B) revealed significant enrichment of functions that correspond to organization of collagen fibrils (*P* \< 3.59 × 10^− 13^) and inflammation of organ (*P* \< 2.07 × 10^− 09^).

### 3.6.3. RORα4 Expression and Immunity in SAT {#s0135}

The association between *RORα4* expression and immunity in adipose tissue is underscored by the pathway analysis identification of significant activation of T lymphocytes signaling pathways, including PKC-θ signaling in T lymphocytes (\~ 30% of pathway enriched, z-score = 2.502, *P* \< 7.22 × 10^− 05^) and inducible T-cell co-stimulator (ICOS)-ICOS-ligand (ICOSL) signaling in T helper (Th) cells (\~ 22% of pathway enriched, z-score = 2.673, *P* \< 6.28 × 10^− 4^) ([Fig. 8](#f0040){ref-type="fig"}A-immune cell signaling). The two significantly enriched T-cell signaling pathways comprised of several overlapping genes suggest that inflammatory signaling may be activated in the SAT of Tg-FABP4-RORα4 *tg*/+ mice as a result of RORα4 overexpression. The heatmap in [Fig. 8](#f0040){ref-type="fig"}B details the fold changes of the genes involved in the two pathways accompanied with expected direction of gene changes when the immune response pathways are activated. Thus, the gene changes identified in the RNA-seq/pathway analysis of the SAT, highlight potential changes associated with T-cell signaling and PKC-θ signaling in *tg*/+ SAT. Recently, there have been several high profile publications utilizing analytical tools to allow for the discrimination of cell subsets and cell composition in complex tissues from their gene expression profiles ([@bb0260], [@bb0305]). We utilized the CIBERSORT gene expression deconvolution analytical tool ([@bb0260]) on our RNA-seq data and plotted the predicted relative frequency of the immune cell subtypes contained in the LM22 signature into a stacked format. CIBERSORT was able to identify a significant increase in CD4 T-cell signature (red) in the SAT from 3/4 of the *tg*/+ Tg-FABP4-RORα4 mice relative to WT littermates ([Fig. 8](#f0040){ref-type="fig"}C and D).

### 3.6.4. RORα4 Expression, Fibrosis and Extracellular Matrix Remodeling in SAT and Liver Tissue {#s0140}

Interestingly, the most significant canonical pathway in both Tg-FABP4-RORα4 *tg*/+ SAT (*P* \< 8.28 × 10^− 8^) and hepatic tissue (*P* \< 5.11 × 10^− 13^) is hepatic fibrosis ([Fig. 7](#f0035){ref-type="fig"}A and C). Although, there is a contrast in the regulation of the genes between the two tissues, this is in accordance with the phenotype. For example, many of the genes that encode the extracellular matrix (ECM) collagen proteins are down-regulated in the Tg-FABP4-RORα4 *tg*/+ SAT, but increased in hepatic tissue ([Fig. 9](#f0045){ref-type="fig"}A). This is highlighted by the differential expression of collagens 4, 5, 6, 18, 19 and 23 ([Fig. 9](#f0045){ref-type="fig"}A), indicating ECM directed molecular mechanisms are affecting fat deposition/energy storage in adipose and liver. Collagen production and regulation is important for adipose development and physiology, as well as adipose plasticity to suit metabolic demands and changes ([@bb0235]). In addition ECM reprogramming is necessary for adipose growth and expansion on energy dense diets. In contrast, collagen production in liver is associated with liver fibrosis. The role of collagens in controlling adiposity is highlighted by loss of collagen XVIII (18) (significantly down-regulated in Tg-FABP4-RORα4 *tg*/+ SAT RNA-seq data) that results in reduced adiposity, ectopic deposition of fat in the liver and hypertriglyceridemia ([@bb0020]). This effect was attributed to reduced fat storage capacity due to perturbations in ECM remodeling and adipocyte development associated with aberrant Wnt/β-catenin signaling ([@bb0020]). Therefore, we used qPCR to validate and demonstrate the (\~ 2--3-fold) significantly decreased expression of the *Col18a1* long, medium and short isoforms in SAT ([Fig. 9](#f0045){ref-type="fig"}B). In contrast, no significant differences in expression were observed in visceral adipose tissue and hepatic tissue ([Fig. 9](#f0045){ref-type="fig"}C and D). The recognized association between aberrant ECM and Wnt/β-catenin signaling in dysfunctional fat deposition was underscored by the RNA-seq analysis in SAT, that identified significant down-regulation of the mRNA encoding secreted frizzled-related protein 5 (Sfrp5) by \~ 5-fold (*P* \< 8.55 × 10^− 56^) (Supplemental Table 1, highlighted in gray). Sfrp5 is a Wnt antagonist that is typically upregulated in adipose during diet-induced obesity. Quantitative PCR analysis further highlighted the attenuated response of *Sfrp5* mRNA expression to a high fat diet challenge in the Tg-FABP4-RORα4 relative to WT mice, and the significantly decreased expression of *Sfrp5* mRNA expression in the SAT from Tg-FABP4-RORα4 relative to wild type on the high fat diet ([Fig. 9](#f0045){ref-type="fig"}E). Overall, the difference in *Sfrp5* induction in Tg-FABP4-RORα4 *tg*/+ mice supports the findings of reduced weight gain associated with specific reduction of SAT fat deposition/expansion in HFD-fed Tg-FABP4-RORα4 *tg*/+ mice, and further suggests that the ability to expand the adipose tissue may be altered in these mice.

In summary, adipose specific transgenic RORα4 expression results in the differential expression of collagen genes (in SAT and liver) that are critical for ECM remodeling, and aberrant *Wnt* signaling - both of which are the underlying factors in altered fat deposition in adipose and hepatic tissues. This is in accord with the very recent study demonstrating the fat microenvironment controls depot specific expansion and tissue mass on obesogenic diets ([@bb0140]), and obesogenic studies on *Wnt* signaling ([@bb0245], [@bb8000]). Furthermore, the two gene expression profiling approaches (qPCR and RNA-seq) identified differential expression of many genes involved in lipid, and glucose homeostasis coupled to ECM remodeling, that are in accord with hepatic fibrosis as the most significantly enriched pathway in Tg-FABP4-RORα4 *tg*/+ SAT and liver. This provides molecular evidence supporting our observations of reduced subcutaneous adiposity, impaired glucose tolerance, ectopic fat accumulation and liver fibrosis. This phenotype highlights important crosstalk between the adipose tissue and the liver, under the modulation of adipose-specific ROR alpha expression.

4. Discussion {#s0145}
=============

The sterol-sensing 'orphan' NR, RORα, is expressed in a number of metabolically active tissues and cell types, including the adipose tissue, muscle, resident tissue macrophages and lymphocytes ([@bb0045]). This NR has been implicated in the regulation of lipid homeostasis and responses to energy dense diets. These factors, and the significance of lipid distribution in adipose depots and lean tissue suggested a potentially important role for RORα in obesity and inflammation. Adipose tissue is important for the regulation of energy homeostasis, in part due to its role in storing triglyceride and secreting many endocrine signaling proteins ([@bb0340]). The local and systemic effects of overexpressing RORα in the adipose tissues of Tg-FABP4-RORα4 mice were examined herein.

Perhaps the most striking result from this study was that Tg-FABP4-RORα4 mice demonstrated a remarkable shift in energy storage and fat distribution from the SAT to non-adipose tissues when challenged with a high fat diet (HFD). Specifically, we observed a subcutaneous lipodystrophy associated with pronounced hepatomegaly and splenomegaly. These changes were also accompanied with decreased overall weight gain and decreased total body fat percentage after HFD. Decreased adiposity and reduced weight gain were most probably a reflection of decreased fat deposition in the subcutaneous depot. Moreover, we also observed significantly higher fasting blood glucose levels and impaired clearance of intra-peritoneally injected glucose in chow-fed Tg-FABP4-RORα4 mice. The glucose clearance impairment was further exacerbated when Tg-FABP4-RORα4 mice were placed on the HFD challenge. However, there were no apparent differences in insulin sensitivity, or circulating insulin levels. Histological analysis confirmed markedly increased accumulation of lipid bodies and signs of portal fibrosis throughout the liver derived from Tg-FABP4-RORα4 mice. In comparison, chow-fed Tg-FABP4-RORα4 mice also presented with splenomegaly and mild hepatomegaly at the end of the study, but do not display changes to the adipose tissues and overall growth. This suggests that the Tg-FABP4-RORα4 mice do not adapt appropriately to the physiological challenges of an energy-dense diet in the context of lipid storage and expansion of adipose tissue, but rather are associated with aberrant energy storage and ectopic fat deposition in other (lean mass) organs.

We utilized two approaches to understand the molecular mechanisms underscoring the observed phenotype of subcutaneous lipodystrophy with accompanying hepatic lipid accumulation and impaired glucose tolerance: targeted qPCR profiling of critical metabolic genes and RNA-seq deep sequencing coupled with pathway analyses.

Focused qPCR analysis of critical metabolic genes in the transgenic SAT (relative to the visceral adipose tissue) identified the selective and significantly decreased expression of several important genes that drive fatty acid biosynthesis, and lipid droplet expansion including *Acs14*, *Dgat2*, *Fasn* and *Scd2* in SAT from the Tg-FABP4-RORα4 line. Furthermore, we identified decreased expression of Rab 18 and the Rab-GAPs, Tbc1d1 and AS160/Tbc1d4. This pattern of expression in adipose tissue has been associated with impaired glycemic control, energy homeostasis, and fat storage ([@bb0110], [@bb0055], [@bb0295]). The subcutaneous specific differential expression of several critical genes provided some insights into the subcutaneous lipodystrophic and glucose intolerant phenotype in the Tg-FABP4-RORα4.

Moreover, additional qPCR profiling revealed the SAT lipodystrophy in the Tg-FABP4-RORα4 mouse model is also associated with increased lipid mobilization and catabolism (relative to WT littermates). For example, we identified increased expression of the genes encoding Cpt2, Pnpla2/ATGL and Adrb3 ([@bb0040], [@bb0145], [@bb0345], [@bb0095], [@bb0100], [@bb0250]). This phenotype was coupled with decreased expression of the (adaptive) thermogenic driver, Ucp1, and Cidea (a marker of increased lipolysis) in brown adipose tissue. This was in accord with increased Ucp1 and Cidea expression in the brown adipose from RORa deficient staggerer mice.

RNA-seq and pathway analysis identified differential expression of many genes involved in lipid localization and transport, glucose metabolism disorder and diabetes in Tg-FABP4-RORα4 SAT. The analysis revealed fibrosis as the most significant pathway in both the SAT and liver. Interestingly, these two tissues display dysfunctional and aberrant (and often reciprocal) regulation of mRNAs encoding ECM collagen proteins; collagen transcripts were down-regulated in the SAT and inversely up-regulated in the liver. Collagen (5, 6 and 18) production and regulation has been implicated in adipose development and physiology, as well as adipose plasticity to suit metabolic demands and changes ([@bb0235]). Aberrant regulation and expression of the extracellular matrix has been demonstrated to drive perturbed adipose reprogramming during obesity and ectopic fat accumulation ([@bb0355], [@bb0020]), ECM-guided molecular mechanisms control the adipogenic pathways and adipocyte size. Specifically, decreased collagen expression in the SAT is in accord with decreased adipocyte size, decreased fat deposition and ectopic fat accumulation ([@bb0020]). In this context we observed the selective decrease in the expression of the mRNAs encoding the short, medium and long forms of *Col18a1* in SAT, but not in visceral adipose tissue or liver.

Furthermore, in this context we identified the significantly decreased expression of (the Wnt antagonist) SFRP5. Down regulation of Wnt signaling and gene expression are associated with adipogenic differentiation (triglyceride storage), and Wnt3A driven dedifferentiation of adipocytes decreases the medium and long forms of Col18a1 ([@bb0020]). In contrast, SFRP5 is normally induced during differentiation to attenuate Wnt signaling ([@bb0065]) and increased during diet-induced obesity ([@bb0175], [@bb0180], [@bb0245], [@bb0265]). Positive Wnt/β-catenin signaling inhibits adipogenesis and Sfrp5 is strongly induced during adipocyte differentiation to counteract it ([@bb0065]). Consequently, Sfrp5-deficient mice are resistant to obesity ([@bb0245]). Interestingly, reduced hepatic SFRP5 (mRNA and protein) expression in morbidly obese women is associated with fatty liver disease (Gutierrez-Vidal et al., 2015). Overall, the difference in *Sfrp5* induction in Tg-FABP4-RORα4 *tg*/+ mice supports the findings of reduced weight gain associated with specific reduction of SAT fat deposition/expansion in HFD-fed Tg-FABP4-RORα4 *tg*/+ mice, and further suggests that the ability to expand the adipose tissue may be altered in these mice.

Conversely, ECM accumulation in the liver is a hallmark of hepatic fibrosis and is associated with hepatic stellate cell activation due to inflammatory signaling ([@bb0030]). ECM reprogramming is necessary for adipose growth and expansion on energy dense diets, and fibrosis in fat tissue is associated with obesity in humans. In children, the presence of collagen in fat is associated with adipocyte size, body mass index and M2 phenotype macrophages, providing further evidence of the association between ECM remodeling and innate immunity ([@bb0355]). Interestingly, loss of collagen 18 (significantly down-regulated by \~ 2--3-fold in Tg-FABP4-RORα4 SAT) results in reduced adiposity, ectopic deposition of fat in the liver and hypertriglyceridemia ([@bb0020]). The phenotype was attributed to reduce fat storage capacity as a result of perturbations in adipocyte development. Interestingly, subcutaneous lipodystrophy, liver steatosis and glucose intolerance are observed in humans with PPAR γ mutations Clearly both are NR dependent, and the metabolic phenotypes have clear parallels ([@bb0335]).

Another interesting feature revealed by the RNA-seq analysis suggests increased T-cell involvement/recruitment in the SAT of Tg-FABP4-RORα4 mice. While RORα is known to regulate inflammation and influence the development of specific lymphocyte populations, for example T helper 17 cells and group 2 innate-like lymphocytes ([@bb0105], [@bb0240]), the biological significance of the increased lymphocyte infiltrate in this mouse model and its relation to the phenotypes remains to be elucidated.

Overall, our collective data suggests that RORα overexpression in the SAT inhibits adipose plasticity, reducing fat deposition and expansion in the tissue, in addition to a shift in lipid homeostasis toward increased lipolysis and mobilization to secondary organs. This potentially perpetuates increased inflammatory signaling and hepatic stellate cell activation in the liver, activating the fibrotic program. The evident adverse effects on the liver are possibly a compensatory mechanism for adipose dysfunction. Pathway analysis of the liver provides support for this hypothesis, predicting inhibition of PPARα signaling and activation of IL-6 signaling.

In humans, there is a positive correlation between greater amounts of lower-body (gluteo-femoral in particular) SAT depots and protection against glucose intolerance and insulin resistance, dyslipidemia and atherosclerosis (reviewed in [@bb0225]). In this context, our data is in line with the view that subcutaneous fat serves as a protective metabolic sink for excess energy and loss of this depot/protection leads to ectopic fat accumulation and impaired glucose clearance. This severely hinders normal tissue function and perpetuates considerable amounts of stress in these organs. Moreover, recent studies report metabolic benefits acquired after SAT transplantation into the intra-abdominal cavity in mice, effectively conferring protection against HFD-induced glucose intolerance and hepatic lipid loading ([@bb0125], [@bb0170], [@bb0360]). For example, mice implanted intra-abdominally with SAT, but not epididymal visceral tissues, were protected against HFD-induced glucose intolerance. These mice were also protected against hepatic triacylglycerol accumulation and inflammation after HFD. However, the underlying mechanism remains obscure as there were no differences in weight gain, glucose uptake by other tissues (including the skeletal muscle), or plasma adipokine concentrations ([@bb0125]).

In light of the metabolic benefits conferred by expansion of SAT and transplantation of SAT into intra-abdominal cavity, it is clear that maintenance (or even supplementation) of SAT integrity offers protection against glucose intolerance and lipid imbalance during metabolic disease. Failure to sustain or expand adequate subcutaneous fat storage adversely impacts glucose tolerance and contributes to ectopic fat accumulation in non-adipose organs such as the liver, increasing susceptibility to inflammatory stress and cancer ([@bb0090], [@bb0125], [@bb0385]). The pathology presented thus far in the Tg-FABP4-RORα4 transgenic mouse model is reminiscent of metabolic dysfunction, such as those of childhood and adolescent obesity. Obese youths typically present with (i) decreased subcutaneous adiposity, (ii) adipose tissue dysfunction accompanied with macrophage, dendritic cells and T-cells recruitment and pro-inflammatory signaling, (iii) increased hepatic lipid deposition/steatosis and muscle lipid deposition, and (iv) impaired glucose tolerance and insulin sensitivity ([@bb0070], [@bb0010], [@bb0315], [@bb0050], [@bb0330]).

Finally, in the context of this adipose specific FABP4 transgenic (over expression) mouse model phenotype, it is essential to discuss the caveats of this animal model. In the last five years several reviews have highlighted the advantages and disadvantages of the different promoters (for example FABP4 vs. adiponectin) for adipose specific gain and loss of function studies including the following: (i) physiological implications of leaky expression in non-adipose tissues and over expression and (ii) ectopic gene position and copy number ([@bb0375], [@bb0155], [@bb0135], [@bb0380], [@bb0205]). Recently it has been demonstrated that the FABP4 and adiponectin Cre produced very similar phenotypes in side by side comparisons ([@bb0160]). However, these qualifications we discussed above need to be considered in the interpretation of any transgenic over expression model.

In conclusion, this animal model study suggests that the NR, RORα4, has a critical regulatory role in the phenotype associated with decreased subcutaneous fat deposition, fatty liver and impaired glucose tolerance. Thus, establishing a role for RORα in these processes will potentially allow us to pharmacological exploit its regulation for treatment of these conditions.
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![Human RORα4 transgene tissue specificity, growth curve and tissue weights of WT versus Tg-FABP4-RORα4 mice on normal chow. (A--C) RNA was extracted from selected tissues (kidney, quadriceps muscle, liver, SAT (inguinal fat), visceral adipose (epididymal fat) and brown adipose (interscapular fat), and examined for relative gene expression of (A) endogenous (mouse) Rorα1 and Rorα4, (B) the transgene (human RORα4) and (C) total RORα (mouse and human) compared to the endogenous control (18s) using real-time PCR (*n* = 3 littermate pairs in duplicate experiments). Statistical analyses were performed using unpaired two-tailed Student\'s *t*-test for (A) and two-way ANOVAs with Bonferroni\'s post-test applied for (B--C) where \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001. (D) Schematic timeline of diet regime employed. (E) Body weight (in grams) of male WT (black) and *tg*/+ (red) mice (*n* = 18 littermate pairs) measured weekly up to 14 weeks of age. Statistical analyses were performed using two-way ANOVAs with Bonferroni\'s post-test applied but results were not significant. (F) Representative images of dissected WT and *tg*/+ littermate pair (chow diet). (G) Mean relative mass/total weight ± S.E.M. of adipose tissues dissected from WT and *tg*/+ mice (*n* = 7 littermate pairs). Statistical analyses were performed on each tissue using unpaired two-tailed Student\'s *t*-test was performed where \**P* \< 0.05.](gr1){#f0005}

![Growth curve of WT and *tg*/+ Tg-FABP4-RORα4 mice on HFD and measurement of adiposity. (A--D) Average weight gain ± S.E.M of WT (black) and *tg*/+ (red) mice. Growth curves plotted to compare HFD and chow diet in (A) WT mice and (B) *tg*/+ mice separately. (C) HFD growth curve on *tg*/+ mice relative to WT (solid circles, *n* = 10 littermate pairs) with commencement of HFD at week 17. (D) Parallel growth curve data of WT and *tg*/+ mice on chow diet (hollow circles, *n* = 7 littermate pairs). Statistical analyses were performed using two-way ANOVAs with Bonferroni\'s post-test applied where \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001. Representative images of (E) dissected WT and *tg*/+ littermate pair at the end of the HFD study (32-week). (F--G) NMR scans were performed on non-fasted live WT and *tg*/+ littermate pairs (HFD) and represented as the mean ± S.E.M. (F) percentage total body fat and (G) percentage lean mass relative to total body weight from *n* = 8 littermate pairs of mice. (H) Mean relative mass/total weight ± S.E.M. of adipose tissues dissected from WT and *tg*/+ littermate pairs after HFD (*n* = 9 littermate pairs). Statistical analysis was performed using unpaired two-tailed Student\'s *t*-test where \*\**P* \< 0.05. (I--J) Assumption-free correlation analysis of visceral and SAT mass in (I) chow 32-week study (*n* = 7 littermate pairs) and (J) HFD study (*n* = 10 littermate pairs). The Pearson correlation R^2^ value reports the fraction of "shared" variance while the *P* value tests the null hypothesis that there is no linear trend between the groups, where a small *P* value indicates a statistical significant linear trend.](gr2){#f0010}

![H&E staining of adipose tissue and weights of non-adipose tissues in HFD-fed WT and *tg*/+ Tg-FABP4-RORα4 mice. (A) Representative images of WT and *tg*/+ SAT stained by H&E. (B) Quantification of cross sectional area of \~ 300 inguinal adipocytes from *n* = 4 littermate pairs of WT and *tg*/+ mice is shown as a histogram of the relative frequency of adipocyte sizes with bin intervals of 1000 μm^2^ and mean and median area measurements. (C) Representative images of WT and *tg*/+ visceral epididymal adipose tissues stained by H&E. (D) Quantification of cross sectional area of \~ 300 epididymal adipocytes from *n* = 4 littermate pairs of WT and *tg*/+ mice is shown as a histogram of the relative frequency of adipocyte sizes with bin intervals of 2000 μm^2^ and mean and median area measurements. Significance was calculated using unpaired two-tailed Student\'s *t*-test where \**P* \< 0.05. (E) Representative image of liver dissected from chow-fed 32-week old WT and *tg*/+ mice. (F) DEXA scanning of dissected livers from chow-fed WT and *tg*/+ mice (*n* = 7 littermate pairs). (G) Mean relative mass/total weight ± S.E.M. of non-adipose tissues (liver, spleen and quadriceps muscle) dissected from chow-fed 32-week old WT and *tg*/+ littermate pairs (*n* = 7 littermate pairs). (H--I) Representative images of (H) liver and (I) spleen dissected from HFD-fed WT and *tg*/+ mice. (J) Mean relative mass/total weight ± S.E.M. of non-adipose tissues (liver, spleen and quadriceps muscle) dissected from WT and *tg*/+ littermate pairs after HFD (*n* = 9 littermate pairs). Statistical significance was calculated using unpaired two-tailed Student\'s *t*-test for where \**P* \< 0.05; \*\**P* \< 0.01.](gr3){#f0015}

![Trichrome staining of HFD livers and glycemic challenge of WT and Tg-FABP4-RORα4 mice. (A) Formalin-fixed and paraffinized liver tissues of HFD-fed WT and *tg*/+ mice were sectioned at 0.7 μm-step intervals and stained for (A) collagen using Masson\'s trichrome staining. Red denotes cytoplasmic staining and the yellow arrowheads indicate collagen staining (blue). Representative images acquired from *n* = 4 littermate pairs are shown. (B and C) Analysis of mean ± S.E.M. fasting plasma (B) triglyceride and (C) NEFAs from 16 weeks chow-fed WT and *tg*/+ mice (*n* = 6 littermate pairs). Significance was calculated using unpaired two-tailed Student\'s *t*-test where \**P* \< 0.05. (D) Fasting blood glucose levels from 6 h-fasted WT (white) and *tg*/+ (black) (*n* = 10 littermate pairs) mice in the chow study (16 weeks old). (E and F) Blood glucose was measured at various times after intra-peritoneal administration of (E) glucose or (F) insulin (*t* = 0) on 6 h-fasted WT (black) and *tg*/+ (red) mice (16 week chow, *n* = 10 littermate pairs). (G) Fasting blood glucose levels from 6 h-fasted WT (white) and *tg*/+ (black) mice (*n* = 5 littermate pairs) in the HFD study. (H and I) Blood glucose was measured at various times after intra-peritoneal administration of (H) glucose or (I) insulin (*t* = 0) on 6 h-fasted WT (black) and *tg*/+ (red) mice in the HFD study (*n* = 5 littermate pairs). Statistical analyses were performed using unpaired two-tailed Student\'s *t*-test for panels D and G and two-way ANOVAs with Bonferroni\'s post-test applied for panels E, F, H and I where \**P* \< 0.05; \*\**P* \< 0.01;\*\*\**P* \< 0.001. (J) Plasma insulin levels of (i) 6 h-fasted (*n* = 5 littermate pairs) and (ii) overnight fasted WT and *tg*/+ littermates (*n* = 8 littermate pairs) from the 32-week chow study. Statistical analysis was performed using unpaired two-tailed Student\'s *t*-test but comparisons were not significant. (K) Plasma insulin levels of overnight fasted WT and *tg*/+ mice in the HFD study (*n* = 8 littermate pairs). Statistical analysis was performed using unpaired two-tailed Student\'s *t*-test but comparisons were not significant.](gr4){#f0020}

![Taqman low density array (TLDA) analysis of mRNA expression from SAT relative to visceral adipose tissue of Tg-FABP4-RORα4 mice on a high fat diet. Relative gene expression (normalized against *Rplp0*) of (A) *Acsl4*, (B) *Dgat2*, (C) *Fasn*, (D) *Scd2*, (E) *Tbc1d1*, (F) *Tbc1d4* and (G) *Rab18*. TLDAs performed as described ([@bb0275], [@bb0280]). Statistical analysis was performed on data acquired from *n* = 4 littermate pairs using unpaired two-tailed Student\'s *t*-test where \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001.](gr5){#f0025}

![Taqman low density array (TLDA) analysis of mRNA expression from subcutaneous adipose and brown adipose tissue from Tg-FABP4-RORα4 relative to WT mice. Relative gene expression of (A--D) *Cpt2*, *Pnpla2*, *Adrb3*, *Ndufb5*, respectively in SAT from HFD fed 32-week *tg*/+ Tg-FABP4-RORα4 and WT littermates (from *n* = 4). TLDAs performed as described ([@bb0275], [@bb0280]). and presented as relative gene expression (normalized against Gusb). Relative gene expression of *Ucp1* and *Cidea*, respectively in brown adipose tissue from *chow* (E--F) and high fat diet (G--H) fed 32-week *tg*/+ Tg-FABP4-RORα4 and WT littermates (*n* = 4). Quantitative PCR was performed on RNA fractionated from interscapular brown adipose tissue, and measured *Ucp1* and *Cidea* expression (using Taqman and SYBR assays), and presented as relative gene expression (normalized against *Gusb*, and *Rplp0*, respectively) in samples from 32-week chow (E--F) and high fat diet fed (G--H) Tg-FABP4-RORα4 and WT littermates (from *n* = 5). Statistical analysis was performed using unpaired two-tailed Student\'s *t*-test where \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001.](gr6){#f0030}

![RNA-seq and ingenuity pathway analysis of HFD inguinal adipose tissue and liver. RNA-seq was performed on RNA isolated from overnight fasted WT and Tg-FABP4-RORα4 (heterozygous) *tg*/+ mice that were in the HFD study (*n* = 4 littermate pairs). (A) The top 15 canonical pathways and biological functions enriched by differentially expressed genes from the RNA-seq analysis comparing WT and *tg*/+ inguinal adipose tissues (HFD) highlighted by ingenuity pathway analysis. Ratio indicates the percentage of differentially expressed genes per any given pathway and *P*-value threshold is set at *P* \< 0.05 derived after Benjamini and Hochberg (B--H) multiple testing correction. (B) Significantly enriched metabolic functions. Orange bars indicate positive z-score (predicted activation) and gray bars indicate no prediction of activation/inhibition state. (C) Significantly enriched canonical pathways and top 10 biological functions associated with differentially expressed genes in *tg*/+ liver (HFD). (D) Gene expression changes in liver tissues of Tg-FABP4-RORα4 vs. WT (*n* = 4 littermate pairs) comparing to expected expression direction of PPAR, IL-6 and PPARα/RXRα signaling activation.](gr7){#f0035}

![Activation of T-cell signaling and CIBERSORT analysis. (A) Significantly enriched immune cell signaling functions in HFD *tg*/+ SAT. Orange bars indicate positive z-score (predicted activation from ingenuity pathway analysis). (B) The heatmap presents differentially expressed in SAT from Tg-FABP4-RORα4 vs. WT (*n* = 4 littermate pairs). Fold changes were shown in log~2~ scale with expected expression direction of PKC-θ and ICOS-ICOSL pathways (activation). (C--D) CIBERSORT analysis of SAT RNA-seq data for the quantification of relative levels (percentage) of 22 immune cell subtypes (LM22 gene signature). Relative percentages are plotted in a stacked format in (C). The data specific to memory resting CD4 T cells listed in C (red module) was extracted and an unpaired two-tailed Student\'s *t*-test was performed to calculate for significance where \**P* \< 0.05.](gr8){#f0040}

![Gene expression changes in the hepatic fibrosis pathway and ECM regulation. (A) Heatmap of differentially expressed genes associated with hepatic fibrosis. Data was extracted from STAR-DESeq2 output (RNA-seq pipeline). Each column represents log~2~ fold-changes comparing SAT and liver tissues of Tg-FABP4-RORα4 vs. WT (*n* = 4 littermate pairs). Relative gene expression of *Col18a1* in (B) SAT, (C) visceral adipose tissue, and (D) liver, respectively from *tg*/+ Tg-FABP4-RORα4 and WT littermates in the HFD study (*n* = 4--5 littermate pairs). Quantitative PCR (utilizing SYBR primers) was performed on RNA fractionated from the tissues and presented as relative gene expression normalized against *Rplp0*. Statistical analysis was performed using unpaired two-tailed Student\'s *t*-test where \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001. (E) Relative gene expression of *Sfrp5* in inguinal SAT from *tg*/+ Tg-FABP4-RORα4 and WT mice in the HFD study (*n* = 4 littermate pairs). Quantitative PCR was performed using TaqMan assays and presented as relative gene expression (normalized against *Gusb*). Statistical analysis was performed using a two-way ANOVA with Bonferroni\'s post-test applied where \*\*\**P* \< 0.001; n.s. denotes non-significant.](gr9){#f0045}
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